EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Spencer D Martin iD, Ishmam Bhuiyan, Maryam Soleimani, Gang Wang

Journal of Clinical Medicine · 28.07.2023 · 12 (15) · 4987

DOI: 10.3390/jcm12154987 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.07.2023. Verfasst von Spencer D Martin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitor (ICI) therapy has revolutionized renal cell carcinoma treatment. Patients previously thought to be palliative now occasionally achieve complete cures from ICI. However, since immunotherapies stimulate the immune system to induce anti-tumor immunity, they often lead to adverse autoimmunity. Furthermore, some patients receive no benefit from ICI, thereby unnecessarily risking adverse events. In many tumor types, PD-L1 expression levels, immune infiltration, and tumor mutation burden predict the response to ICI and help inform clinical decision making to better target ICI to patients most likely to experience benefits. Unfortunately, renal cell carcinoma is an outlier, as these biomarkers fail to discriminate between positive and negative responses to ICI therapy. Emerging biomarkers such as gene expression profiles and the loss of pro-angiogenic proteins VHL and PBRM-1 show promise for identifying renal cell carcinoma cases likely to respond to ICI. This review provides an overview of the mechanistic underpinnings of different biomarkers and describes the theoretical rationale for their use. We discuss the effectiveness of each biomarker in renal cell carcinoma and other cancer types, and we introduce novel biomarkers that have demonstrated some promise in clinical trials.

Schlagwörter

Stichwörter der Autor:innen

PBRM-1PD-L1PD1T cellVHLbiomarkerimmune checkpoint inhibitorimmunotherapyrenal cell carcinomatumor mutation burden

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  • Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
  • Division of Medical Oncology, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
  • British Columbia Cancer Vancouver Centre, Vancouver, BC V5Z 4E6, Canada.

ORCID-Profile: Spencer D Martin

Zitieren

APA

Martin, S. D., Bhuiyan, I., Soleimani, M., & Wang, G. (2023). Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma. Journal of Clinical Medicine, 12(15), 4987. https://doi.org/10.3390/jcm12154987

Vancouver

Martin SD, Bhuiyan I, Soleimani M, Wang G. Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma. Journal of Clinical Medicine. 2023;12(15):4987. doi:10.3390/jcm12154987

BibTeX
@article{Martin2023,
  author = {Martin, Spencer D and Bhuiyan, Ishmam and Soleimani, Maryam and Wang, Gang},
  title = {Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {15},
  pages = {4987},
  doi = {10.3390/jcm12154987}
}
Kostenlos starten →